In an age-matched case–control study of PV patients, investigators observed that the presence of ≥1 TET2 or ASXL1 or DNMT3A mutations significantly increased the risk of thrombosis, and that PV patients with a TET2 mutation had a significantly higher risk of thrombosis [13]. This evidence concerns the gene TET2 and Venous thrombosis.